We believe this site might serve you best::

United States

United States

Choose language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

ApoTox-Glo™ Triplex Assay

G6320

Assess Viability, Cytotoxicity and Apoptosis in One Assay

  • Easy to implement with an "add-mix-measure" protocol
  • Normalize data with a built-in control
  • Flexible and easily automated

Size

Catalog number selected: G6320

$ 585.00 Your price: Log In

Add to Helix Add to Helix
ApoTox-Glo™ Triplex Assay
10ml
$ 585.00
Your price: Log In
Change Configuration

Three Effective Assays in One Single Product

The ApoTox-Glo™ Triplex Assay combines three assay chemistries to easily assess viability, cytotoxicity and apoptosis events in the same cell-based assay well. First, viability and cytotoxicity are determined by measuring two differential protease biomarkers simultaneously with the addition of a single nonlytic reagent containing two peptide substrates. The live-cell protease activity is restricted to intact viable cells and is measured using a fluorogenic, cell-permeant peptide substrate (GF-AFC Substrate). The substrate enters intact cells, where it is cleaved to generate a fluorescent signal proportional to the number of living cells. This live-cell protease activity marker becomes inactive upon loss of membrane integrity and leakage into the surrounding culture medium.

A second, cell-impermeant, fluorogenic peptide substrate (bis-AAF-R110 Substrate) is used simultaneously to measure dead-cell protease activity that has been released from cells that have lost membrane integrity. This results in ratiometric, inversely correlated measures of cell viability and cytotoxicity. The ratio of viable cells to dead cells is independent of cell number and, therefore, can be used to normalize data. A second reagent containing luminogenic DEVD-peptide substrate for caspase-3/7 and Ultra-Glo™ Recombinant Thermostable Luciferase is added. Caspase-3/7 cleavage of the substrate releases luciferin, which is a substrate for luciferase and generates light. The light output, measured with a luminometer, correlates with caspase-3/7 activation as a key indicator of apoptosis.

Cat.# G6320 contains sufficient reagents for 100 assays in a 96-well plate format or 400 assays in a 384-well format. Cat.# G6321 contains sufficient reagents for 500 assays in a 96-well plate format or 2,000 assays in a 384-well format.

    Measure Viability, Cytotoxicity, and Apoptosis in the Same Sample Well

    8141MA-W
    Necrosis Results

    Ionomycin treatment of Jurkat cells for 6 hours results in dose-dependent decrease in viability and increase in cytotoxicity with no caspase-3/7 activation, consistent with primary necrosis.

    8140MA-W
    Apoptosis Results

    Staurosporine treatment of Jurkat cells for 6 hours results in a dose-dependent decrease in viability and increase in cytotoxicity with an increase in caspase-3/7 activity consistent with apoptosis.

    8170MA-W
    Cytostasis Results

    Camptothecin treatment of Jurkat cells for 48 hours results in dose-dependent decrease in viability, no cytotoxicity and increase in caspase-3/7 activity, consistent with cell-cycle arrest and early-phase apoptosis.

    Protocols

    Specifications

    You are viewing: 10ml Change Configuration

    What's in the box?

    Item Part # Size

    GF-AFC Substrate

    G608A 1 x 10μl

    bis-AAF-R110 Substrate

    G609A 1 x 10μl

    Assay Buffer

    G610A 1 x 10ml

    Caspase-Glo® 3/7 Buffer

    G810A 1 x 10ml

    Caspase-Glo® 3/7 Substrate

    G811A 1 x 1 bottle

    SDS

    Choose language:

    Certificate of Analysis

    Search for Specific Certificate:

    View more results
    No results
    Loading…

    Use Restrictions

    For Research Use Only. Not for Use in Diagnostic Procedures.

    Storage Conditions

    BB

    Patents and Disclaimers

    U.S. Pat. Nos. 7,416,854, 7,553,632 and other patents pending.

    U.S. Pat. Nos. 6,602,677, 7,241,584, 8,030,017 and 8,822,170 and other patents and patents pending.

    Specifications

    You are viewing: 5 × 10ml Change Configuration

    What's in the box?

    Item Part # Size

    GF-AFC Substrate

    G608B 1 x 50μl

    bis-AAF-R110 Substrate

    G609B 1 x 50μl

    Assay Buffer

    G610A 2 x 10ml

    Caspase-Glo® 3/7 Buffer

    G810A 5 x 10ml

    Caspase-Glo® 3/7 Substrate

    G811A 5 x 1 bottle

    SDS

    Choose language:

    Certificate of Analysis

    Search for Specific Certificate:

    View more results
    No results
    Loading…

    Use Restrictions

    For Research Use Only. Not for Use in Diagnostic Procedures.

    Storage Conditions

    BB

    Patents and Disclaimers

    U.S. Pat. Nos. 7,416,854, 7,553,632 and other patents pending.

    U.S. Pat. Nos. 6,602,677, 7,241,584, 8,030,017 and 8,822,170 and other patents and patents pending.

    Resources

    workflow-background

    Small Molecule Drug Discovery Workflow

    Choose your country

    Americas

    Brazil
    Brazil
    Canada
    Canada
    United States
    United States

    Pacific Asia

    Australia
    Australia
    India
    India
    Japan
    Japan
    Korea, Republic of
    Korea, Republic of
    Singapore
    Singapore

    Europe

    Austria
    Austria
    Belgium
    Belgium
    Denmark
    Denmark
    Estonia
    Estonia
    Finland
    Finland
    France
    France
    Germany
    Germany
    Iceland
    Iceland
    Italy
    Italy
    Luxembourg
    Luxembourg
    Netherlands
    Netherlands
    Norway
    Norway
    Poland
    Poland
    Spain
    Spain
    Sweden
    Sweden
    Switzerland
    Switzerland
    United Kingdom
    United Kingdom